Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 5 studies | 37% ± 21% | |
| endothelial cell | 5 studies | 24% ± 3% | |
| non-classical monocyte | 4 studies | 24% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 19% ± 2% | |
| natural killer cell | 3 studies | 19% ± 2% | |
| type I pneumocyte | 3 studies | 16% ± 1% | |
| naive B cell | 3 studies | 18% ± 1% | |
| B cell | 3 studies | 20% ± 2% | |
| ciliated cell | 3 studies | 33% ± 16% | |
| basal cell | 3 studies | 24% ± 5% | |
| glutamatergic neuron | 3 studies | 34% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 3403.87 | 459 / 459 | 100% | 45.27 | 1118 / 1118 |
| esophagus | 100% | 3063.41 | 1445 / 1445 | 100% | 40.23 | 183 / 183 |
| ovary | 100% | 1688.99 | 180 / 180 | 100% | 35.20 | 430 / 430 |
| prostate | 100% | 2485.26 | 245 / 245 | 100% | 35.45 | 502 / 502 |
| stomach | 100% | 2114.13 | 359 / 359 | 100% | 31.77 | 286 / 286 |
| uterus | 100% | 2555.98 | 170 / 170 | 100% | 38.16 | 459 / 459 |
| thymus | 100% | 3112.04 | 653 / 653 | 100% | 48.42 | 604 / 605 |
| intestine | 100% | 2743.51 | 966 / 966 | 100% | 34.57 | 526 / 527 |
| bladder | 100% | 2641.33 | 21 / 21 | 100% | 32.07 | 503 / 504 |
| kidney | 100% | 2783.93 | 89 / 89 | 100% | 33.17 | 899 / 901 |
| lung | 100% | 2630.62 | 577 / 578 | 100% | 36.58 | 1154 / 1155 |
| brain | 100% | 2422.86 | 2635 / 2642 | 100% | 37.96 | 705 / 705 |
| skin | 100% | 4183.67 | 1809 / 1809 | 99% | 31.63 | 467 / 472 |
| pancreas | 97% | 1060.25 | 317 / 328 | 100% | 33.47 | 178 / 178 |
| adrenal gland | 100% | 1968.90 | 258 / 258 | 96% | 25.92 | 220 / 230 |
| liver | 100% | 1070.87 | 225 / 226 | 93% | 13.27 | 378 / 406 |
| adipose | 100% | 3670.60 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2812.26 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 30.79 | 29 / 29 |
| spleen | 100% | 2977.03 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 35.64 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 17.58 | 1 / 1 |
| muscle | 100% | 1787.73 | 799 / 803 | 0% | 0 | 0 / 0 |
| heart | 97% | 1420.48 | 836 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 20.65 | 77 / 80 |
| peripheral blood | 74% | 1204.05 | 690 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0032435 | Biological process | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
| GO_0090083 | Biological process | regulation of inclusion body assembly |
| GO_1902176 | Biological process | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway |
| GO_0061084 | Biological process | negative regulation of protein refolding |
| GO_0006457 | Biological process | protein folding |
| GO_0007030 | Biological process | Golgi organization |
| GO_0051438 | Biological process | regulation of ubiquitin-protein transferase activity |
| GO_0010977 | Biological process | negative regulation of neuron projection development |
| GO_0050821 | Biological process | protein stabilization |
| GO_0051444 | Biological process | negative regulation of ubiquitin-protein transferase activity |
| GO_0031397 | Biological process | negative regulation of protein ubiquitination |
| GO_0048471 | Cellular component | perinuclear region of cytoplasm |
| GO_0016020 | Cellular component | membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0005634 | Cellular component | nucleus |
| GO_0016234 | Cellular component | inclusion body |
| GO_0005829 | Cellular component | cytosol |
| GO_0030314 | Cellular component | junctional membrane complex |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000774 | Molecular function | adenyl-nucleotide exchange factor activity |
| GO_0019901 | Molecular function | protein kinase binding |
| GO_0031625 | Molecular function | ubiquitin protein ligase binding |
| GO_0051087 | Molecular function | protein-folding chaperone binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | BAG5 |
| Protein name | BCL2-associated athanogene 5 BAG family molecular chaperone regulator 5 (BAG-5) (Bcl-2-associated athanogene 5) BAG family molecular chaperone regulator 5 (Bcl-2-associated athanogene 5) |
| Synonyms | KIAA0873 hCG_25497 |
| Description | FUNCTION: Co-chaperone for HSP/HSP70 proteins. It functions as a nucleotide-exchange factor promoting the release of ADP from HSP70, thereby activating HSP70-mediated protein refolding . Has an essential role in maintaining proteostasis at junctional membrane complexes (JMC), where it may function as a scaffold between the HSPA8 chaperone and JMC proteins enabling correct, HSPA8-dependent JMC protein folding (By similarity). Inhibits both auto-ubiquitination of PRKN and ubiquitination of target proteins by PRKN (By similarity). . |
| Accessions | ENST00000299204.6 [Q9UL15-1] A8CGI4 Q9UL15 A0A024R6M6 ENST00000337322.5 [Q9UL15-1] ENST00000445922.2 [Q9UL15-1] |